Study of acetylsalicylic acid and clopidogrel treatment after left atrial appendage closure in patients with atrial fibrillation and chronic kidney disease

3 1 1 1 1

What is this study about?

This clinical trial focuses on patients with Atrial Fibrillation who have undergone a procedure called Left Atrial Appendage Closure and are receiving kidney dialysis treatment. The study aims to find the best blood-thinning medication strategy after this heart procedure to prevent blood clots while minimizing bleeding risks.

The study will test two blood-thinning medications: acetylsalicylic acid (commonly known as aspirin) and clopidogrel. These medications help prevent blood clots from forming. Both medications are taken as tablets by mouth. The study will compare different durations of taking these medications, including using both medications together for different periods versus using just one medication.

Patients who participate will be monitored for several important health outcomes, including stroke, blood clots, bleeding events, and heart-related complications. The study will also look at brain function using MRI scans and cognitive tests to ensure the treatment approach is safe and effective. The medications will be given in specific doses – 75 mg daily for each medication – and patients will be followed for several months to evaluate the safety and effectiveness of different medication combinations.

1 Initial procedure

You will undergo a left atrial appendage closure procedure (a heart procedure to prevent blood clots)

After the procedure, you will receive two medications: acetylsalicylic acid (aspirin) and clopidogrel, both taken by mouth

2 First month after procedure

You will continue taking both medications (aspirin and clopidogrel) for the first 30 days

Regular dialysis treatment will continue as usual

Medical staff will monitor your health status

3 One-month assessment

You will be assigned to one of two treatment groups

Group 1: Continue taking only one medication until 6 months after the procedure

Group 2: Continue taking both medications until 6 months after the procedure

4 Six-month period

Regular health assessments will be conducted

Brain imaging (MRI) will be performed to check for any changes

Cognitive function testing will be conducted using a special examination

Your dialysis access site will be monitored

5 After six months

A decision will be made about continuing or stopping medication

Regular follow-up visits will continue to monitor your health

The study will track your progress for several years to ensure safety and effectiveness

Who Can Join the Study?

  • Patient must have had a successful closure of the left atrial appendage (a small pouch in the heart) using either an Amplatzer or WATCHMAN device within the past 37 days
  • Patient must have end-stage kidney disease and be receiving regular treatment through either:
    • Hemodialysis (blood cleaning through a machine)
    • Peritoneal dialysis (cleaning blood through the belly lining)
  • Patient must be 18 years of age or older
  • Patient must be willing to follow all study requirements, including:
    • Following the assigned treatment plan
    • Attending all follow-up visits
  • Patient must be willing to provide written informed consent to participate in the study

Who Cannot Join the Study?

  • Age below 18 years or above 65 years
  • Presence of blood clots in the heart chambers
  • Recent major bleeding within the last 30 days
  • Active stomach or intestinal ulcers
  • Severe allergic reaction to blood-thinning medications
  • Inability to take antiplatelet medications (medications that prevent blood clots)
  • Planned major surgery within the next 6 months
  • Life expectancy less than 1 year
  • Previous stroke within the last 3 months
  • Severe heart valve disease
  • Active cancer requiring treatment
  • Pregnancy or planning to become pregnant
  • Severe liver disease
  • Uncontrolled high blood pressure
  • Current participation in another clinical trial
  • Mental conditions that prevent understanding of study requirements

Where you can join this trial?

Verified and Recommended Sites

Site Name City Country Status
Samodzielny Publiczny Szpital Kliniczny Nr 4 W Lublinie Lublin Poland

Verified Sites

Other Sites

Site Name City Country Status
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy Warsaw Poland
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Warsaw Poland
Slaskie Centrum Chorob Serca W Zabrzu Zabrze Poland
Gornoslaskie Centrum Mwdyczne Katowice Poland
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy Warsaw Poland
Uniwersytecki Szpital Kliniczny W Poznaniu Poznan Poland
Svtgezct Pmtcsaihm Sfk z oztw Wejherowo Poland
Ugofuncetbcily Cyxnppo Kmadufqnq Gdansk Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Poland Poland
Not yet recruiting
28.09.2022

Trial locations

Dual Antiplatelet Therapy (DAPT)
This is a combination of two medications that help prevent blood clots. It’s commonly used after certain heart procedures to reduce the risk of complications. The therapy works by making blood platelets less sticky and less likely to form clots.

Single Antiplatelet Therapy (SAPT)
This is a single medication that helps prevent blood clots. It’s a simpler form of blood-thinning treatment compared to DAPT, usually involving one medication that prevents platelets from sticking together. This therapy is often used for long-term prevention of blood clots after the initial treatment period.

Left Atrial Appendage Closure (LAAC)
While not a medication, this is a medical procedure that involves placing a device to close off a small pouch in the heart called the left atrial appendage. This procedure is performed to reduce the risk of blood clots forming in this area and potentially causing a stroke, particularly in patients who have kidney disease requiring dialysis.

Investigated diseases:

Atrial Fibrillation – A heart rhythm disorder where the upper chambers of the heart beat irregularly and often rapidly, out of sync with the lower chambers. The condition occurs when electrical signals in the heart become chaotic, causing an irregular heartbeat pattern. This irregular rhythm can allow blood to pool in the heart chambers, which may lead to the formation of blood clots. The condition can be persistent or come and go in episodes. People with atrial fibrillation may experience heart palpitations, shortness of breath, and reduced ability to exercise.

Trial ID:
2024-516384-93-00
Protocol code:
CKD/1458/21
NCT ID:
NCT05660811
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A Study to Test How Well PKN605 Works and How Safe It Is in Patients with Atrial Fibrillation

    Recruiting

    2 1
    Germany The Netherlands
  • Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Denmark Germany Hungary Italy The Netherlands +1